Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089131 | 0.78 | ALDH1A1 (0.38) | ALDH1A1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3100725 | 0.76 | CYP2D6 (0.36) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3089108 | 0.74 | CA1 (0.30) | — | |
| SCHEMBL4710589 | 0.70 | CA1 (0.42) | ALDH1A1 | |
| SCHEMBL1399160 | 0.68 | CA1 (0.52) | ALDH1A1 | |
| SCHEMBL4635514 | 0.68 | CA1 (0.52) | ALDH1A1 | |
| SCHEMBL575702 | 0.66 | CA1 (0.50) | ALDH1A1 | |
| SCHEMBL31106933 | 0.66 | CA1 (0.50) | ALDH1A1 | |
| SCHEMBL575488 | 0.66 | CA1 (0.46) | ALDH1A1 | |
| SCHEMBL28662148 | 0.66 | CA1 (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396296-B1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2396296-B1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9096619-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096619-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096619-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9067871-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9067871-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9067871-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140031331-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031331-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20130184238-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184238-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184238-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-07-18 | — | — | US | disclosed |
| CN-102395558-A | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO KG | 2012-03-28 | — | — | CN | disclosed |
| EP-2396296-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-12-21 | — | — | EP | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| WO-2010092180-A1 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092180-A1 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031331-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, GFPT1, BCAT1 | ALDH1A1 1318/4885CYP2D6 341/4885SLC6A2 44/4885 |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | AADAT, GFPT1, BCAT1 | ALDH1A1 1487/4885CYP2D6 323/4885SLC6A2 48/4885 |
| US-20130184238-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, GFPT1, BCAT1 | ALDH1A1 1318/4885CYP2D6 341/4885SLC6A2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.